Study guide
6.1 Acute Coronary Syndromes & Myocardial Infarction
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
6.1 Acute Coronary Syndromes & Myocardial Infarction
Key Takeaways Explain This Topic AI
The Fourth Universal Definition of Myocardial Infarction classifies acute ischaemia into five types: Type 1 results from atherothrombotic plaque rupture or erosion, while Type 2 arises from myocardial oxygen supply-demand mismatch without acute plaque disruption.
STEMI is diagnosed by new J-point ST-segment elevation in two contiguous leads: >=2.5 mm in men <40, >=2.0 mm in men >=40, and >=1.5 mm in women in leads V2-V3, or >=1.0 mm in other leads; posterior MI requires posterior leads V7-V9 demonstrating ST elevation >=0.5 mm.
Right ventricular infarction complicates up to 50% of inferior STEMIs (proximal RCA occlusion), presenting with the clinical triad of hypotension, clear lung fields, and raised JVP; it requires aggressive IV volume resuscitation while vasodilators (nitrates) and diuretics are strictly contraindicated.
Primary PCI is indicated when medical contact-to-balloon time is <=120 minutes; if anticipated transfer exceeds 120 minutes, immediate systemic fibrinolysis must be administered within 10 minutes followed by routine angiography within 2-24 hours.
Mechanical complications occur 3-7 days post-MI: acute mitral regurgitation from posteromedial papillary muscle rupture causes catastrophic pulmonary oedema without a prominent murmur, whereas ventricular septal rupture produces a loud pansystolic murmur with an oxygen saturation step-up from RA to RV.
Last updated: September 2026
Acute coronary syndromes (ACS) encompass a spectrum of myocardial ischaemia ranging from unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) to transmural ST-elevation myocardial infarction (STEMI). Mastery of the pathophysiological distinctions, electrocardiographic diagnostic thresholds, evidence-based pharmacotherapy, and post-infarction mechanical complications is essential for MRCP(UK) Part 1.
- 1. Pathophysiology & Universal Definition of Myocardial Infarction
- Plaque Rupture vs. Plaque Erosion
Coronary atherothrombosis arises from two distinct histopathological mechanisms:
Plaque Rupture (~70% of fatal MIs): Classically features a thin fibrous cap (<65 μm), large necrotic lipid core, and heavy macrophage infiltration. Degradation of the extracellular matrix by matrix metalloproteinases precipitates cap disruption, exposing thrombogenic core contents (tissue factor, type I collagen) to circulating platelets. Platelet activation occurs via glycoprotein VI and GP Ib-IX-V, followed by cross-linking of glycoprotein IIb/IIIa receptors by fibrinogen. This produces an occlusive red (fibrin- and erythrocyte-rich) thrombus, most commonly causing STEMI.
Plaque Erosion (~30% of MIs): Characterized by a thick fibrous cap rich in extracellular matrix (hyaluranan, proteoglycans) and vascular smooth muscle cells, devoid of a large lipid core. Endothelial denudation and neutrophil extracellular traps (NETs) trigger platelet activation, yielding a non-occlusive white (platelet-rich) thrombus. Plaque erosion is increasingly recognized in premenopausal women, younger individuals, and active smokers, typically presenting as NSTEMI.
Fourth Universal Definition of Myocardial Infarction
The consensus definition requires myocardial injury—evidenced by a rise and/or fall of cardiac troponin (cTnI or cTnT) with at least one value above the 99th percentile upper reference limit (URL)—occurring in the setting of acute myocardial ischaemia, substantiated by at least one of:
Symptoms of acute myocardial ischaemia (e.g., retrosternal crushing pain, diaphoresis, nausea).
New ischaemic ECG changes (ST-segment deviations or T-wave inversions).
Development of pathological Q waves.
Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality (RWMA) in an ischaemic distribution.
Identification of an intraluminal coronary thrombus by angiography or autopsy.
MI Classification Pathophysiological Mechanism Clinical Scenarios & Distinguishing Features
Type 1 Primary atherothrombotic event Plaque rupture, ulceration, fissure, or erosion with intraluminal thrombus
Type 2 Supply-demand ischaemic mismatch Coronary vasospasm, spontaneous coronary artery dissection (SCAD), severe anaemia, septic shock, hypertensive emergency, prolonged tachyarrhythmias
Type 3 Presumed cardiac death Sudden cardiac death with symptoms suggestive of ischaemia and presumed new ECG changes, before biomarkers could be drawn
Type 4a Percutaneous Coronary Intervention (PCI)-related cTn elevation > 5 × 99th percentile URL within 48h of index procedure, plus new ischaemic ECG changes, new Q waves, or angiographic complication
Type 4b / 4c Stent thrombosis (4b) or Restenosis (4c) Angiographic or autopsy confirmation of thrombus within stent (4b) or in-stent restenosis > 50% stenosis with ischaemia (4c)
Type 5 Coronary Artery Bypass Graft (CABG)-related cTn elevation > 10 × 99th percentile URL within 48h of CABG, plus new pathological Q waves, new angiographic graft/native occlusion, or imaging loss of myocardium
- 2. Electrocardiographic Diagnosis: STEMI, Posterior MI & RV Infarction
- Standard ST-Elevation Cut-offs
ST elevation must be measured at the J-point in at least two contiguous leads:
Leads V2–V3:
- Men < 40 years: ≥ 2.5 mm \ge 2.5\text{ mm} ≥ 2.5 mm ( 0.25 mV 0.25\text{ mV} 0.25 mV )
- Men ≥ 40 \ge 40 ≥ 40 years: ≥ 2.0 mm \ge 2.0\text{ mm} ≥ 2.0 mm ( 0.20 mV 0.20\text{ mV} 0.20 mV )
- Women (any age): ≥ 1.5 mm \ge 1.5\text{ mm} ≥ 1.5 mm ( 0.15 mV 0.15\text{ mV} 0.15 mV )
All other leads (Limb leads I, II, III, aVF, aVL and precordial V1, V4–V6): ≥ 1.0 mm \ge 1.0\text{ mm} ≥ 1.0 mm ( 0.10 mV 0.10\text{ mV} 0.10 mV ) regardless of sex or age.
Reciprocal ST depression: Strongly corroborates STEMI (e.g., ST depression in leads I and aVL during acute inferior STEMI, or leads II, III, aVF during anterior STEMI).
Posterior Myocardial Infarction
Occlusion of the left circumflex (LCx) or distal right coronary artery (RCA) causes transmural ischaemia of the posterior basal LV wall. Standard 12-lead ECG does not directly view the posterior wall:
Indirect changes in V1–V3: Horizontal ST depression, tall upright broad R waves ( R / S ratio > 1 R/S \text{ ratio} > 1 R / S ratio > 1 ), and prominent upright T waves (the inverted mirror image of anterior transmural STEMI).
Posterior Leads (V7–V9): Electrode V7 at the posterior axillary line, V8 at the mid-scapular line, and V9 at the left paraspinal border (all in the 5th intercostal space). Diagnostic threshold: ST elevation ≥ 0.5 mm \ge 0.5\text{ mm} ≥ 0.5 mm ( 0.05 mV 0.05\text{ mV} 0.05 mV ) confirms acute posterior STEMI and mandates immediate reperfusion.
Right Ventricular Infarction
Right ventricular involvement occurs in 30–50% of inferior STEMIs due to proximal occlusion of a dominant RCA (before the acute marginal branches).
ECG Confirmation: Right-sided precordial lead V4R (5th right intercostal space, midclavicular line) demonstrates ST elevation ≥ 1.0 mm \ge 1.0\text{ mm} ≥ 1.0 mm .
Haemodynamic Profile: The ischaemic RV fails to pump forward volume, leading to elevated right atrial pressure and diminished LV filling. The patient presents with the classic triad of hypotension, clear lung fields, and raised jugular venous pressure (Kussmaul's sign) .
Therapeutic Rules: The RV is strictly preload-dependent. Nitrates, diuretics, morphine, and beta-blockers are strictly contraindicated ; their administration causes catastrophic precipitous hypotension. Management demands urgent primary PCI and aggressive volume loading with intravenous crystalloids (500–1000 mL boluses of 0.9 % 0.9\% 0.9% saline). If hypoperfusion persists despite volume expansion, inotropic support with dobutamine is initiated.
- 3. Reperfusion Strategies & Evidence-Based Pharmacology
- Reperfusion Pathways in STEMI
Primary PCI: Reperfusion strategy of choice if wire crossing can be achieved within 120 minutes of STEMI diagnosis (door-to-balloon time < 90 minutes < 90\text{ minutes} < 90 minutes in PCI centres; < 120 minutes < 120\text{ minutes} < 120 minutes if transferred from a non-PCI centre).
Intravenous Fibrinolysis: Indicated when anticipated delay to primary PCI exceeds 120 minutes. Fibrin-specific agents (tenecteplase weight-adjusted bolus, alteplase, or reteplase) must be administered within 10 minutes of STEMI diagnosis ("needle time"). Absolute contraindications: prior intracranial haemorrhage, ischaemic stroke within 6 months, known central nervous system neoplasm/AVM, active internal bleeding, or suspected aortic dissection.
Pharmacoinvasive Strategy: Following fibrinolysis, transfer all patients immediately to a PCI centre:
Rescue PCI: Indicated for failed fibrinolysis ( < 50 % < 50\% < 50% ST-segment resolution in the lead with maximum ST elevation at 60–90 minutes, ongoing ischaemia, or haemodynamic instability).
Routine Angiography: Performed within 2–24 hours after successful fibrinolysis.
Dual Antiplatelet Therapy (DAPT) & Anticoagulation
Aspirin: Loading dose 300 mg chewed/oral, followed by 75 mg once daily indefinitely.
Potent P2Y12 Inhibitors:
Ticagrelor: 180 mg loading dose, then 90 mg twice daily. Direct, reversible P2Y12 receptor antagonist. Associated with transient dyspnoea and asymptomatic ventricular pauses.
Prasugrel: 60 mg loading dose, then 10 mg once daily. Irreversible prodrug thienopyridine with faster, more potent platelet inhibition. Superior to ticagrelor in ACS undergoing PCI (ISAR-REACT 5 trial). Contraindications: Prior stroke or transient ischaemic attack (TIA) due to fatal intracranial bleed risk. Dose reduction to 5 mg daily if age ≥ 75 \ge 75 ≥ 75 years or weight < 60 kg < 60\text{ kg} < 60 kg .
Clopidogrel: 300–600 mg load, 75 mg daily. Reserved for patients requiring triple therapy (concurrent oral anticoagulation), high bleeding risk, or when newer agents are contraindicated.
Anticoagulation:
Primary PCI: Unfractionated heparin (UFH; 70–100 IU/kg IV adjusted by ACT) or bivalirudin (direct thrombin inhibitor).
NSTEMI / Non-invasive: Fondaparinux (2.5 mg SC daily, selective factor Xa inhibitor) offers the lowest bleeding profile; during PCI, a bolus of UFH is required to prevent catheter-induced thrombosis.
4. NSTEMI Risk Stratification & Invasive Strategy Timing
NSTEMI and UA require immediate risk stratification using validated clinical risk scores:
GRACE 2.0 Score: Calculates 6-month in-hospital and post-discharge mortality based on 8 variables: age, heart rate, systolic blood pressure, serum creatinine, Killip class, cardiac arrest at admission, ST-segment deviation, and elevated cardiac biomarkers.
Invasive Timing (ESC / NICE Guidelines):
Immediate Invasive Strategy ( < 2 hours < 2\text{ hours} < 2 hours ): Hemodynamic instability or cardiogenic shock, recurrent/refractory angina despite medical therapy, life-threatening ventricular arrhythmias, mechanical complications, or acute heart failure due to myocardial ischaemia.
Early Invasive Strategy ( < 24 hours < 24\text{ hours} < 24 hours ): High-risk patients with a GRACE score > 140 > 140 > 140 , dynamic ST- or T-wave changes, or transient ST elevation.
Selective Invasive Strategy: Low-risk patients (GRACE score ≤ 140 \le 140 ≤ 140 without recurrent ischaemia) undergo outpatient non-invasive functional imaging (stress echocardiography, cardiac MRI, or CT coronary angiography).
5. Mechanical Complications of Acute Myocardial Infarction
Mechanical complications develop predominantly 3 to 7 days post-MI (bimodal peak: < 24 hours < 24\text{ hours} < 24 hours and day 3–5) during peak macrophage-mediated phagocytosis and necrotic myocardial thinning before mature collagen scar formation.
Complication Culprit Vessel & Site Clinical Presentation & Physical Signs Diagnostic Findings Definitive Management
Free Wall Rupture (FWR) LAD (anterior) or RCA (lateral/inferior); full-thickness transmural MI Sudden electromechanical dissociation (EMD/PEA arrest), profound hypotension, tamponade (Beck's triad: elevated JVP, muffled sounds, pulsus paradoxus) Transthoracic echo: large pericardial effusion with right atrial/ventricular diastolic collapse Immediate pericardiocentesis, emergency cardiac surgical repair; mortality > 80 % > 80\% > 80%
Ventricular Septal Rupture (VSR) LAD (apical septum) or RCA (basal septum) Rapid biventricular failure, cardiogenic shock; harsh, loud pansystolic murmur at left lower sternal border with palpable thrill ( > 50 % > 50\% > 50% ) Echo: left-to-right shunt; Right heart catheterization: O 2 \text{O}_2 O 2 saturation step-up > 5 – 10 % > 5\text{–}10\% > 5 – 10% from RA to RV Afterload reduction (IV nitroprusside), intra-aortic balloon pump (IABP), emergent surgical or percutaneous closure
Papillary Muscle Rupture (Acute MR) Posteromedial papillary muscle (single blood supply via PDA); RCA or LCx Sudden catastrophic pulmonary oedema, dyspnoea, shock; soft early/mid-systolic murmur at apex (frequently silent due to rapid left atrial pressure equalisation); no thrill Echo: flail mitral leaflet, torrential MR jet, hyperdynamic LV; PCWP tracing: giant systolic v waves Afterload reduction, IABP / temporary mechanical circulatory support (Impella), urgent surgical mitral valve replacement
True LV Aneurysm LAD (apical/anterior transmural MI); occurs late (2–12 weeks) Heart failure, refractory ventricular arrhythmias, systemic thromboembolism; persistent double apical impulse ECG: persistent ST elevation > 6 weeks > 6\text{ weeks} > 6 weeks with deep Q waves; Echo: thin, dyskinetic scarred LV segment Anticoagulation (warfarin/DOAC for mural thrombus), antiarrhythmics, surgical reconstruction/aneurysmectomy
False Aneurysm (Pseudoaneurysm) Free wall rupture contained entirely by adherent parietal pericardium/thrombus High risk of sudden fatal rupture; narrow neck connecting to LV chamber Echo/CMR: narrow orifice with bidirectional high-velocity Doppler flow Emergency surgical repair